Biomarkers in Samples From Patients With B-Cell Acute Lymphoblastic Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01505699|
Recruitment Status : Completed
First Posted : January 6, 2012
Last Update Posted : May 17, 2017
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
PURPOSE: This research study is studying biomarkers in samples from patients with acute lymphoblastic leukemia enrolled on ECOG-2993 clinical trial.
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: RNA analysis Genetic: cytogenetic analysis Genetic: microarray analysis Other: laboratory biomarker analysis|
- To identify microRNAs that behave as oncogenes or as tumor suppressor genes in B-lineage acute lymphoblastic leukemia (ALL) in vitro and in vivo.
- To examine if single microRNA or signatures of microRNA correspond to different clinical outcomes in cytogenetically distinct B-ALL groups.
OUTLINE: RNA from archived samples are analyzed for microRNA expression profile in vitro and in vivo.
|Study Type :||Observational|
|Actual Enrollment :||186 participants|
|Official Title:||Micro RNA Expression Analysis in B-Lineage Adult Acute Lymphoblastic Leukemia From ALL Trial, E2993, Including Patients With Various Cytogenetic and Molecular Abnormalities|
|Actual Study Start Date :||January 6, 2012|
|Actual Primary Completion Date :||February 6, 2012|
|Actual Study Completion Date :||February 6, 2012|
- Comprehensive view of microRNA expression by cytogenetic subgroup [ Time Frame: 1 year ]
- MicroRNA expression in relation to clinical outcome [ Time Frame: 1 year ]
- Differential microRNA expression between normal B-cells and progenitors compared to B-ALL [ Time Frame: 1 year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01505699
|Principal Investigator:||Hans-Guido Wendel, MD||Memorial Sloan Kettering Cancer Center|